Adlai Nortye Ltd - ANL Operating Profitability

Public company logo of Adlai Nortye Ltd. (ANL)

Outsourcing production and testing allows Adlai Nortye Ltd. (ANL) to remain a flexible scientific hub. The operating profitability of operational processes exhibits volatility, where -133.90 captures the current value of the indicator. Growth prospects rely on pricing power driven by the unique inhibitor buparlisib. Meanwhile, the company's environmental policy is limited to standard laboratory controls and a transition to digital documentation.

Adlai Nortye Limited (ANL): Operating Return on Sales from 02/21/2024 to 11/20/2026

Financial and market metric breakdowns for Adlai Nortye Ltd. (ANL)

- stock quotes and analyst forecast:
Fundamental company analysis:Adlai Nortye Ltd., ANL
Brand item of Adlai Nortye Limited

Adlai Nortye Ltd. (ANL) is currently transitioning to the commercial launch of oncology drugs following the completion of global Phase III clinical trials. An analysis of the operating profit margin, calculated as the ratio of operating income to revenue, allows for an assessment of the business model's efficiency before financial expenses, helping investors timely identify the risk of purchasing an impaired asset with degrading profitability.

Competitors of Adlai Nortye Ltd.

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|Operating Profit Rate ACTU|CTOR - Operating Profitability|Profitability of Operations tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operating Profitability|FATE: Operating Profit Ratio|WHWK (Aadi Bioscience, Inc.) - Operating Margin|TCRX (TScan Therapeutics) - Operating Profit Ratio|Operating Profitability Champions Oncology (CSBR)|Profitability of Operations XBiotech USA|Operating Profitability CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Operating Return on Sales|RADX - Operating Profitability|ARTV - Operating Margin|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin